VolitionRx Limited saw its shares fall 16.8% in premarket trade on Monday after announcing the terms of a public equity offering priced at $1.55 per share. The Henderson, Nevada-based epigenetics company said the transaction is structured to include both common stock and detachable warrants.
The deal will have VolitionRx issue 2,960,000 shares of common stock along with warrants allowing holders to buy up to another 1,480,000 shares. The combined offering price for each common share and accompanying half warrant is $1.55. Each full warrant carries an exercise price of $1.55 per share, will be exercisable immediately on issuance, and will expire five years from the issuance date.
VolitionRx indicated the offering attracted commitments from a mix of new and existing investors. Maxim Group LLC is serving as the sole placement agent for the sale.
Before placement agent fees and other offering expenses, and not counting any proceeds that might come from warrant exercises, the company expects to generate approximately $4.6 million in gross proceeds from the sale of the common stock and accompanying warrants. If all warrants are exercised on a cash basis, VolitionRx could receive an additional $2.3 million in gross proceeds; the company explicitly cautioned that there is no assurance any warrants will be exercised.
The company stated the offering is expected to close on June 9, 2026, subject to customary closing conditions. No further timing or additional financing details were provided beyond the expected close date and the terms described.
VolitionRx is identified in the filing as a company focused on epigenetics technology. The announced financing and the attached warrants lay out a potential path for incremental cash if warrant holders elect to exercise, but also represent immediate dilution risk for existing shareholders given the new share issuance and the possibility of further share issuance through warrant exercise.
Quick analysis
- Offering size and terms are explicit: 2,960,000 shares and rights to 1,480,000 additional shares via warrants at $1.55.
- Gross proceeds before fees are approximately $4.6 million, with a potential additional $2.3 million if warrants are fully exercised.
- Maxim Group LLC acts as sole placement agent; offering expected to close June 9, 2026, subject to customary conditions.